It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Migraine occurs 2–3 times more often in females than in males and is in many females associated with the onset of menstruation. The steroid hormone, 17β-estradiol (estrogen, E2), exerts its effects by binding and activating several estrogen receptors (ERs). Calcitonin gene-related peptide (CGRP) has a strong position in migraine pathophysiology, and interaction with CGRP has resulted in several successful drugs for acute and prophylactic treatment of migraine, effective in all age groups and in both sexes.
Methods
Immunohistochemistry was used for detection and localization of proteins, release of CGRP and PACAP investigated by ELISA and myography/perfusion arteriography was performed on rat and human arterial segments.
Results
ERα was found throughout the whole brain, and in several migraine related structures. ERβ was mainly found in the hippocampus and the cerebellum. In trigeminal ganglion (TG), ERα was found in the nuclei of neurons; these neurons expressed CGRP or the CGRP receptor in the cytoplasm. G-protein ER (GPER) was observed in the cell membrane and cytoplasm in most TG neurons. We compared TG from males and females, and females expressed more ER receptors. For neuropeptide release, the only observable difference was a baseline CGRP release being higher in the pro-estrous state as compared to estrous state. In the middle cerebral artery (MCA), we observed similar dilatory ER-responses between males and females, except for vasodilatory ERβ which we observed only in female arteries.
Conclusion
These data reveal significant differences in ER receptor expression between male and female rats. This contrasts to CGRP and PACAP release where we did not observe discernable difference between the sexes. Together, this points to a hypothesis where estrogen could have a modulatory role on the trigeminal neuron function in general rather than on the acute CGRP release mechanisms and vasomotor responses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Glostrup Research Institute, Department of Clinical Experimental Research, Glostrup, Denmark; Lund University Hospital, Division of Experimental Vascular Research, Department of Clinical Sciences, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
2 Lund University Hospital, Division of Experimental Vascular Research, Department of Clinical Sciences, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987); University of California at Irvine, Department of Pharmacology, School of Medicine, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
3 Glostrup Research Institute, Department of Clinical Experimental Research, Glostrup, Denmark (GRID:grid.266093.8)
4 Glostrup Research Institute, Department of Clinical Experimental Research, Glostrup, Denmark (GRID:grid.266093.8); University of Copenhagen, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
5 Glostrup Research Institute, Department of Clinical Experimental Research, Glostrup, Denmark (GRID:grid.5254.6); Lund University Hospital, Division of Experimental Vascular Research, Department of Clinical Sciences, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987); Lund University Hospital, Department of Internal Medicine, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
6 Glostrup Research Institute, Department of Clinical Experimental Research, Glostrup, Denmark (GRID:grid.411843.b)